Business Case

Portfolio assessment for a leading, clinical-stage Ophthalmology Biotech to understand portfolio planning implications of a dynamic marketplace

Our client, a mid-sized biotech was developing a DryAMD treatment. DryAMD was expecting several near-term launches and our client sought LSC’s guidance to understand the impact on the commercial opportunity of these new entrants. LSC was able to identify the place in therapy for our client’s therapy, as well as key competitive differentiators/treatment gaps patients and physicians were expected to confront in the new marketplace. Ultimately, LSC was able to develop an NPV calculation to guide client investment decisions.